Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Tsuji

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
BMC Gastroenterology|October 23, 2019
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinomaHiroaki Takaya, Tadashi Namisaki, Mitsuteru Kitade, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 16, 2025
Initial Experience With Nalmefene in Alcohol-Related Liver Disease: A Real-World Retrospective StudyJunichi Hanatani, Tadashi Namisaki, Hiroaki Takaya, et al.
Anticancer Research|October 3, 2022
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With LenvatinibYuki Fujimoto, Tadashi Namisaki, Soichi Takeda, et al.
International Journal of Molecular Sciences|September 9, 2022
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary CholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
International Journal of Molecular Sciences|October 16, 2025
Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLDMasafumi Oyama, Tadashi Namisaki, Akihiko Shibamoto, et al.
United European Gastroenterology Journal|November 3, 2018
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and CHiroaki Takaya, Hideto Kawaratani, Yuki Tsuji, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 13, 2026
Impact of the Number of Remaining Natural Teeth on Decompensation and Survival in Patients With Compensated Liver CirrhosisTatsuya Nakatani, Tadashi Namisaki, Hiroaki Takaya, et al.
International Journal of Molecular Sciences|August 8, 2020
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic SteatohepatitisYukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya, et al.
Current Issues in Molecular Biology|February 27, 2026
Creatinine/Cystatin C Ratio as a Surrogate Marker for Sarcopenia in Hepatitis-C-Associated Liver Cirrhosis After Achieving a Sustained Virologic ResponseAritoshi Koizumi, Tadashi Namisaki, Akihiko Shibamoto, et al.
Journal of Clinical Medicine|November 13, 2021
The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven CriteriaHiroaki Takaya, Tadashi Namisaki, Soichi Takeda, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
BMC Gastroenterology|October 23, 2019
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinomaHiroaki Takaya, Tadashi Namisaki, Mitsuteru Kitade, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 16, 2025
Initial Experience With Nalmefene in Alcohol-Related Liver Disease: A Real-World Retrospective StudyJunichi Hanatani, Tadashi Namisaki, Hiroaki Takaya, et al.
Anticancer Research|October 3, 2022
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With LenvatinibYuki Fujimoto, Tadashi Namisaki, Soichi Takeda, et al.
International Journal of Molecular Sciences|September 9, 2022
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary CholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
International Journal of Molecular Sciences|October 16, 2025
Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLDMasafumi Oyama, Tadashi Namisaki, Akihiko Shibamoto, et al.
United European Gastroenterology Journal|November 3, 2018
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and CHiroaki Takaya, Hideto Kawaratani, Yuki Tsuji, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 13, 2026
Impact of the Number of Remaining Natural Teeth on Decompensation and Survival in Patients With Compensated Liver CirrhosisTatsuya Nakatani, Tadashi Namisaki, Hiroaki Takaya, et al.
International Journal of Molecular Sciences|August 8, 2020
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic SteatohepatitisYukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya, et al.
Current Issues in Molecular Biology|February 27, 2026
Creatinine/Cystatin C Ratio as a Surrogate Marker for Sarcopenia in Hepatitis-C-Associated Liver Cirrhosis After Achieving a Sustained Virologic ResponseAritoshi Koizumi, Tadashi Namisaki, Akihiko Shibamoto, et al.
Journal of Clinical Medicine|November 13, 2021
The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven CriteriaHiroaki Takaya, Tadashi Namisaki, Soichi Takeda, et al.
Pageof 11